Related references
Note: Only part of the references are listed.Neuregulin-1 receptor tyrosine kinase ErbB4 is upregulated in midbrain dopaminergic neurons in Parkinson disease
Candan Depboylu et al.
NEUROSCIENCE LETTERS (2012)
Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses
Andrew Jabbour et al.
EUROPEAN JOURNAL OF HEART FAILURE (2011)
Systemic administration of neuregulin-1β1 protects dopaminergic neurons in a mouse model of Parkinson's disease
Thomas Carlsson et al.
JOURNAL OF NEUROCHEMISTRY (2011)
Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease
Candan Depboylu et al.
JOURNAL OF NEUROIMMUNOLOGY (2011)
Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia
T. Kato et al.
MOLECULAR PSYCHIATRY (2011)
Biodistribution and brain permeability of the extracellular domain of neuregulin-1-β1
Thomas W. Roesler et al.
NEUROPHARMACOLOGY (2011)
Subchronic Peripheral Neuregulin-1 Increases Ventral Hippocampal Neurogenesis and Induces Antidepressant-Like Effects
Ian Mahar et al.
PLOS ONE (2011)
A Phase II, Randomized, Double-Blind, Multicenter, Based on Standard Therapy, Placebo-Controlled Study of the Efficacy and Safety of Recombinant Human Neuregulin-1 in Patients With Chronic Heart Failure
Runlin Gao et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
ErbB receptors and the development of the nervous system
Carmen Birchmeier
EXPERIMENTAL CELL RESEARCH (2009)
IN SITU HYBRIDIZATION REVEALS DEVELOPMENTAL REGULATION OF ErbB1-4 mRNA EXPRESSION IN MOUSE MIDBRAIN: IMPLICATION OF ErbB RECEPTORS FOR DOPAMINERGIC NEURONS
Y. Abe et al.
NEUROSCIENCE (2009)
Expression of ErbB4 in substantia nigra dopamine neurons of monkeys and humans
Yingjun Zheng et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2009)
Neuregulin 1 in neural development, synaptic plasticity and schizophrenia
Lin Mei et al.
NATURE REVIEWS NEUROSCIENCE (2008)
Protocol for the MPTP mouse model of Parkinson's disease
Vernice Jackson-Lewis et al.
NATURE PROTOCOLS (2007)
Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates
S Behrstock et al.
GENE THERAPY (2006)
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
AE Lang et al.
ANNALS OF NEUROLOGY (2006)
Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease
L. Novikova et al.
NEUROSCIENCE (2006)
Neuregulin-1-β1 enters brain and spinal cord by receptor-mediated transport
AJ Kastin et al.
JOURNAL OF NEUROCHEMISTRY (2004)
The neuregulin receptor, ErbB4, is not required for normal development and adult maintenance of the substantia nigra pars compacta
S Thuret et al.
JOURNAL OF NEUROCHEMISTRY (2004)
Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality
H Tidcombe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease
SS Gill et al.
NATURE MEDICINE (2003)
Neuregulin and ErbB receptor signaling pathways in the nervous system
A Buonanno et al.
CURRENT OPINION IN NEUROBIOLOGY (2001)
The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety
S Przedborski et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
JH Kordower et al.
SCIENCE (2000)
Share Paper
